Ranitidine, sold under the brand name Zantac among others, is a medication used to decrease stomach acid production. It is used in the treatment of peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome. It can be given by mouth, injection into a muscle, or injection into a vein. In September 2019, the probable carcinogen N-nitrosodimethylamine (NDMA) was discovered in ranitidine products from a number of manufacturers, resulting in recalls. In April 2020, ranitidine was withdrawn from the United States market and suspended in the European Union and Australia due to these concerns. A reformulated ranitidine was approved in Australia in October 2024, and in the United States in November 2025. Common side effects include headaches, and pain or burning sensation if given by injection. Serious side effects may include cancer, liver problems, a slow heart rate, pneumonia, and the potential of masking stomach cancer. It is also linked to an increased risk of Clostridioides difficile colitis. Ranitidine is an H2 histamine receptor antagonist that works by blocking histamine, thus decreasing the amount of acid released by cells of the stomach. Ranitidine was discovered in England in 1976 and came into commercial use in 1981. It is on the World Health Organization's List of Essential Medicines.
Medical uses Relief of heartburn Short-term and maintenance therapy of gastric and duodenal ulcers With nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce the risk of ulceration Proton-pump inhibitors (PPIs) are more effective for the prevention of NSAID-induced ulcers. Pathologic gastrointestinal (GI) hypersecretory conditions such as Zollinger–Ellison syndrome Gastroesophageal reflux disease (GORD or GERD) Erosive esophagitis Part of a multidrug regimen for Helicobacter pylori eradication to minimise the risk of duodenal ulcer recurrence Recurrent postoperative ulcer Upper GI bleeding For prevention of acid-aspiration pneumonitis during surgery, it can be administered preoperatively. The drug increases gastric pH, but generally has no effect on gastric volume. In a 2009 meta-analysis comparing the net benefit of PPIs and ranitidine to reduce the risk of aspiration before anaesthesia, ranitidine was found to be more effective than PPIs in reducing the volume of gastric secretions. Ranitidine may have an anti-emetic effect when administered preoperatively. Prevention of stress-induced ulcers in critically ill patients Used together with diphenhydramine as secondary treatment for anaphylaxis; after first-line epinephrine.
Adverse effects These adverse effects for ranitidine have been reported as events in clinical trials:
Central nervous system Rare reports have been made of ranitidine causing malaise, dizziness, somnolence, insomnia, and vertigo. In severely ill, elderly patients, cases of reversible mental confusion, agitation, depression, and hallucinations have been reported.
Cardiovascular Arrhythmias such as tachycardia, bradycardia, atrioventricular block, and premature ventricular beats have also been reported.
Gastrointestinal Drugs in the H2 receptor blocker class of medicines have the potential to cause vitamin B12 deficiency, secondary to a reduction in food-bound vitamin B12 absorption. Elderly patients taking H2 receptor antagonists are more likely to require B12 supplementation than those not taking such drugs. H2 blockers may also reduce the absorption of drugs (azole antifungals, calcium carbonate) that require an acidic stomach. In addition, multiple studies suggest the use of H2 receptor antagonists such as ranitidine may increase the risk of infectious diarrhoea, including traveller's diarrhoea and salmonellosis. A 2005 study found that by suppressing acid-mediated breakdown of proteins, ranitidine may lead to an elevated risk of developing food or drug allergies, due to undigested proteins then passing into the GI tract, where sensitisation occurs. Patients who take these agents develop higher levels of immunoglobulin E against food, whether they had prior antibodies or not. Even months after discontinuation, an elevated level of IgE in 6% of patients was still found in the study.
Liver Cholestatic hepatitis, liver failure, hepatitis, and jaundice have been noted, and require immediate discontinuation of the drug. Blood tests can reveal an increase in liver enzymes or eosinophilia, although in rare instances, severe cases of hepatotoxicity may require a liver biopsy.
Lungs Ranitidine and other histamine H2 receptor antagonists may increase the risk of pneumonia in hospitalised patients. Ranitidine increases the risk of community-acquired pneumonia in adults and children.
Blood Thrombocytopenia is a rare but known side effect. Drug-induced thrombocytopenia usually takes weeks or months to appear, but may appear within 12 hours of drug intake in a sensitised individual. Typically, the platelet count falls to 80% of normal, and thrombocytopenia may be associated with neutropenia and anemia.
Skin Rash, including rare cases of erythema multiforme, and rare cases of hair loss and vasculitis have been seen.
Precautions
Disease-related concerns Relief of symptoms due to the use of ranitidine does not exclude the presence of a gastric malignancy. In addition, with kidney or liver impairment, ranitidine must be used with caution. It should be avoided in patients with porphyria, as it may precipitate an attack.
Children In children, the use of gastric acid inhibitors has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia. A cohort analysis including over 11,000 neonates reported an association of H2 blocker use, and an increased incidence of necrotizing enterocolitis in very-low-birth-weight (VLBW) neonates. In addition, about a six-fold increase in mortality, necrotizing enterocolitis, and infection such as sepsis, pneumonia, urinary tract infection was reported in patients receiving ranitidine in a cohort analysis of 274 VLBW neonates.
Drug tests Ranitidine may return a false positive result with some commercial urine drug screening kits for testing for drugs of abuse.
Cancer-causing due to inherent instability
… excerpt ends here. Continue reading the full article.




